Oracle’s $553B Backlog Soars 325%! 03/21/26

Oracle’s $553B Backlog Soars 325%! 03/21/26 Key Stories: Oracle, the enterprise software and cloud computing giant, just dropped a bombshell with its fiscal third-quarter earnings report, revealing an astounding $553 billion in remaining purchase obligations. That’s a jaw-dropping 325% increase year-over-year. This immense backlog, largely driven by demand for its cloud infrastructure services, is being interpreted by many as a powerful validation of its long-term growth trajectory and a sign that its strategic investments are yielding substantial future revenue commitments. Read more Digging deeper into Oracle’s impressive numbers, that $553 billion backlog isn’t just a headline figure; it’s seen as a strong indicator that the company’s aggressive pivot into cloud computing and its strategic investments in artificial intelligence infrastructure are truly paying off. This massive surge in future commitments, up 325% from a year ago, essentially answers the question of whether this backlog is a ‘gold mine’ or a ‘mirage,’ firmly putting it in the ‘gold mine’ camp following their earnings. The market is clearly recognizing Oracle’s increasing relevance in the booming AI and enterprise cloud space. Read more Shifting gears to the biotech sector, Monte Rosa Therapeutics, ticker GLUE, is making waves with a significant new supply agreement. The company announced it’s partnering with pharmaceutical giant Johnson & Johnson to evaluate MRT-2359, Monte Rosa’s experimental drug, alongside J&J’s ERLEADA in a Phase 2 trial for metastatic castration-resistant prostate cancer. This collaboration comes on the heels of additional positive clinical data for MRT-2359 presented at ASCO GU 2026, bolstering confidence in its potential. Monte Rosa shares are currently trading around $15.63, having delivered an impressive 169.5% return over the past year, underscoring investor enthusiasm for its pipeline and strategic partnerships in this crucial therapeutic area. Read more Keywords: AI, ERLEADA, GLUE, JNJ, Johnson & Johnson, MRT-2359, Monte Rosa Therapeutics, ORCL, Oracle, Phase 2 trial, artificial intelligence, backlog, biotech, clinical data, cloud computing, cloud infrastructure, earnings, enterprise software, growth trajectory, investor confidence, pharmaceutical, prostate cancer, purchase obligations, revenue, strategic investments, supply agreementThe post Oracle’s $553B Backlog Soars 325%! 03/21/26 first appeared on Rapid Money Radio.